Ticker: AVBP

ArriVent BioPharma, Inc. (NASDAQ: AVBP) - Snapshot Short take: the company is ramping clinical and discovery programs (primarily firmonertinib), funding the build with public raises and an ATM program while burning cash rapidly. Clinical interim data are encouraging; the income statement shows he...